We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-12.52%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.5B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
1.63%
Top 10 Hldgs %
41.52%
Holding
149
New
17
Increased
43
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$108M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$75.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$71.1M
4
LLY icon
Eli Lilly
LLY
+$70.2M
5
UNH icon
UnitedHealth
UNH
+$67.9M

Top Sells

Rank Stock Value
1
HNT
HEALTH NET INC
HNT
+$205M
2
VTRS icon
Viatris
VTRS
+$149M
3
AFFX
Affymetrix Inc
AFFX
+$75.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$59.4M
5
BMY icon
Bristol-Myers Squibb
BMY
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.92%
2 Financials 0.22%
3 Technology 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$130B
$487M 5.13%
7,624,900
-770,100
-9% -$48.6M
HCA icon
2
HCA Healthcare
HCA
$90.7B
$448M 4.71%
5,737,100
-218,500
-4% -$15.3M
AMGN icon
3
Amgen
AMGN
$212B
$431M 4.54%
2,876,000
-45,000
-2% -$6.69M
BSX icon
4
Boston Scientific
BSX
$68.9B
$423M 4.45%
22,479,700
-1,951,200
-8% -$34.3M
ABBV icon
5
AbbVie
ABBV
$471B
$422M 4.45%
7,395,700
-52,800
-0.7% -$2.94M
AGN
6
DELISTED
Allergan plc
AGN
$422M 4.44%
1,572,715
+148,000
+10% +$42.4M
BIIB icon
7
Biogen
BIIB
$32.1B
$397M 4.18%
1,526,300
+83,800
+6% +$22.1M
CELG
8
DELISTED
Celgene Corp
CELG
$378M 3.97%
3,774,077
+108,627
+3% +$11.2M
GILD icon
9
Gilead Sciences
GILD
$166B
$277M 2.92%
3,019,200
-402,200
-12% -$36.3M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$260M 2.74%
1,870,600
-404,500
-18% -$59.4M
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
$217M 2.28%
6,776,100
+112,000
+2% +$3.94M
TMO icon
12
Thermo Fisher Scientific
TMO
$215B
$203M 2.14%
1,435,000
+55,000
+4% +$7.37M
INCY icon
13
Incyte
INCY
$25.3B
$200M 2.1%
2,755,078
-77,900
-3% -$5.81M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$73.1B
$192M 2.02%
533,000
+50,000
+10% +$20.6M
LLY icon
15
Eli Lilly
LLY
$1.09T
$183M 1.93%
2,541,300
+928,300
+58% +$70.2M
WCG
16
DELISTED
Wellcare Health Plans, Inc.
WCG
$177M 1.86%
1,903,300
+557,100
+41% +$46.2M
ISRG icon
17
Intuitive Surgical
ISRG
$128B
$166M 1.75%
2,491,200
+340,200
+16% +$21.1M
ESRX
18
DELISTED
Express Scripts Holding Company
ESRX
$166M 1.75%
2,421,000
+239,000
+11% +$17.2M
VRTX icon
19
Vertex Pharmaceuticals
VRTX
$124B
$149M 1.56%
1,869,400
+1,196,400
+178% +$108M
ILMN icon
20
Illumina
ILMN
$29.3B
$146M 1.54%
925,200
+23,644
+3% +$3.61M
TEVA icon
21
Teva Pharmaceuticals
TEVA
$39.4B
$144M 1.52%
2,696,000
+250,000
+10% +$14.7M
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$144M 1.51%
1,120,000
– –
A icon
23
Agilent Technologies
A
$39.6B
$139M 1.47%
3,495,000
+169,000
+5% +$6.44M
WMGI
24
DELISTED
Wright Medical Group Inc
WMGI
$139M 1.46%
8,345,110
+99,999
+1% +$1.85M
MGLN
25
DELISTED
Magellan Health Services, Inc.
MGLN
$130M 1.36%
1,909,000
+76,000
+4% +$4.57M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2016 Portfolio in Review

As of Q1 2016, OrbiMed held 149 positions worth $9.5B, down 14% from $11B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q1 2016 filing shows 17 new, 43 increased, 27 reduced and 8 closed positions. Its largest new stake was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M. The largest sale was HEALTH NET INC, an estimated $205M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q1 2016 buy was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M.
  • OrbiMed added most to Vertex Pharmaceuticals in Q1 2016, an estimated $108M increase.
  • OrbiMed's biggest Q1 2016 reduction was Viatris, cutting an estimated $149M.
  • OrbiMed fully exited HEALTH NET INC in Q1 2016, selling an estimated $205M.
  • OrbiMed's ten largest holdings make up 42% of its $9.5B portfolio in Q1 2016.
  • OrbiMed opened 17 new positions and closed 8 in Q1 2016.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $9.5B.

Based on OrbiMed's 13F filing for Q1 2016, filed 16 May 2016.